BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25387568)

  • 1. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
    Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
    Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
    Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.
    Yuan Y; Sheng Z; Liu Z; Zhang X; Xiao Y; Xie J; Zhang Y; Xu T
    J Cancer; 2020; 11(13):3762-3770. PubMed ID: 32328181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
    Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.
    Shao L; Cui Y; Li H; Liu Y; Zhao H; Wang Y; Zhang Y; Ng KM; Han W; Ma D; Tao Q
    Clin Cancer Res; 2007 Oct; 13(19):5756-62. PubMed ID: 17908965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
    Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
    Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
    Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
    Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
    Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
    J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer.
    Li P; Liu K; Li L; Yang M; Gao W; Feng J; Lv Y; Qu X; Kong B
    Int J Gynecol Cancer; 2011 Oct; 21(7):1248-55. PubMed ID: 21841490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.
    Niu J; Li H; Zhang Y; Li J; Xie M; Li L; Qin X; Qin Y; Guo X; Jiang Q; Liu Y; Chen S; Huang X; Han W; Ruan G
    Leuk Res; 2011 Jun; 35(6):771-6. PubMed ID: 21168207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities.
    Xie J; Yuan Y; Liu Z; Xiao Y; Zhang X; Qin C; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2014 Apr; 16(4):402-9. PubMed ID: 23907292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMTM5-v1 induces apoptosis in cervical carcinoma cells.
    Shao L; Guo X; Plate M; Li T; Wang Y; Ma D; Han W
    Biochem Biophys Res Commun; 2009 Feb; 379(4):866-71. PubMed ID: 19124004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bax-interacting factor-1 inhibits cell proliferation and promotes apoptosis in prostate cancer cells.
    Xu L; Wang Z; He SY; Zhang SF; Luo HJ; Zhou K; Li XF; Qiu SP; Cao KY
    Oncol Rep; 2016 Dec; 36(6):3513-3521. PubMed ID: 27748942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis.
    Cai B; Xiao Y; Li Y; Zheng S
    Oncol Lett; 2017 Aug; 14(2):1536-1542. PubMed ID: 28789377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
    Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
    Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma.
    Yu C; Wu G; Dang N; Zhang W; Zhang R; Yan W; Zhao Y; Gao L; Wang Y; Beckwith N; Yuan J; Yao L
    Cancer Biol Ther; 2011 Aug; 12(4):304-13. PubMed ID: 21623166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association of
    Liu TF; Lin T; Ren LH; Li GP; Peng JJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):856-862. PubMed ID: 33047719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.